Effect of Meditation as an Adjunct to Cardiac Rehabilitation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstituto Dante Pazzanese de Cardiologia

About this trial

Cardiovascular rehabilitation is a well-established standard of care that significantly reduces morbidity and mortality while improving quality of life. However, integrating behavioral interventions into physical training may offer additional benefits for autonomic regulation and emotional well-being.

This randomized clinical trial aims to investigate the efficacy of adding a brief, guided mindfulness meditation session to a standard cardiovascular rehabilitation program. The study seeks to determine whether this combined intervention enhances blood pressure control, improves perceived quality of life, and increases patient adherence compared to standard rehabilitation alone.

Participants newly enrolled in the Cardiac Rehabilitation Service will be randomized into two groups. Both groups will undergo a standard 12-week regimen of aerobic and resistance training combined with optimized medical therapy. The intervention group will additionally receive 15 minutes of voice-guided mindfulness meditation at the end of each exercise session. Key outcome measures include blood pressure variability, quality of life scores (assessed via EQ-5D), and attendance rates.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients of both sexes, aged 18 years or older.

Newly enrolled in the Phase II Cardiac Rehabilitation Program.

Clinically stable condition with medical clearance to perform aerobic and resistance exercises.

Diagnosis of cardiovascular disease (e.g., coronary artery disease, post-myocardial infarction, post-cardiac surgery, or stable heart failure) warranting rehabilitation.

Disqualifiers

Current regular practice of meditation, yoga, or other mind-body techniques (defined as formal practice more than once a week in the previous 3 months).

Current participation in other psychological or behavioral intervention clinical trials.

Severe cognitive impairment or psychiatric disorders that preclude understanding of the meditation instructions or group participation (e.g., dementia, untreated psychosis).

Unstable clinical conditions such as unstable angina, uncontrolled arrhythmias, or decompensated heart failure that contraindicate physical exercise.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Meditation

    Behavioral

    Participants in this group will undergo the standard cardiac rehabilitation program consisting of 60 minutes of aerobic and resistance training, twice a week for 12 weeks. Additionally, they will participate in a 15-minute voice-guided mindfulness meditation session immediately following each exercise session. Participants also receive optimized medical therapy.

  • Standard Cardiac Rehabilitation

    Procedure/Surgery

    Participants in this group will undergo the standard cardiac rehabilitation program consisting of 60 minutes of aerobic and resistance training, twice a week for 12 weeks, along with optimized medical therapy. This group does not receive the guided meditation intervention.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Experimental: Meditation + RehabilitationExperimental treatment 1 intervention
Group B: Active Comparator: Standard RehabilitationActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Quality of Life Scores (EuroQol EQ-5D Visual Analogue Scale)

Quality of life is assessed using the EuroQol Five Dimensions Questionnaire (EQ-5D). This instrument includes the EQ Visual Analogue Scale (EQ-VAS), a quantitative measure of the participant's self-rated health status. The EQ-VAS scores range from a minimum of 0 to a maximum of 100, where 0 represents 'the worst health you can imagine' and 100 represents 'the best health you can imagine'. Higher scores indicate better health outcomes and higher quality of life.

Time frame
Baseline and Week 12

Secondary outcomes

1

Change in Systolic and Diastolic Blood Pressure

Assessment of both systolic and diastolic blood pressure parameters using a validated digital oscillometric device. Measurements are recorded in millimeters of mercury (mmHg). Reductions in both systolic and diastolic values indicate clinical improvement.

Time frame
Baseline and Week 12
2

Rate of Rehabilitation Adherence

Time frame
Through study completion, an average of 12 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.